Woodcock Fears Biosimilars Program To 'Explode' Without More Resources

FDA drug center chief Janet Woodcock said FDA is worried that the biosimilar program is going to “explode” and the agency won't have the resources to keep up, speaking to lawmakers at a House Energy and Commerce health panel hearing Thursday (Feb. 4). Woodcock's statement responded to questions form E&C Ranking Democrat Frank Pallone (NJ), who pressed the FDA official on whether outstanding guidances on labeling and interchangeability and the fact that only one biosimilar has been approved since the...